The estimated Net Worth of Group L Pcolumn Group Iii, ... is at least $3.74 Миллион dollars as of 17 February 2021. Group Iii owns over 10,000 units of Constellation Pharmaceuticals Inc stock worth over $3,370,278 and over the last 4 years Group sold CNST stock worth over $369,500.
Group has made over 1 trades of the Constellation Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Group sold 10,000 units of CNST stock worth $369,500 on 17 February 2021.
The largest trade Group's ever made was selling 10,000 units of Constellation Pharmaceuticals Inc stock on 17 February 2021 worth over $369,500. On average, Group trades about 5,000 units every 0 days since 2020. As of 17 February 2021 Group still owns at least 99,155 units of Constellation Pharmaceuticals Inc stock.
You can see the complete history of Group Iii stock trades at the bottom of the page.
Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo... и Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include: